Returning to health?

The private equity firm is leading a buyout of drugs market research company IMS. But oldstyle LBO financing is missing. The buyers are putting in a whopping 40% as equity. The rest is coming courtesy of Goldman and mostly from funds it manages, not its own balance sheet.